A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection
Phase 2
Completed
- Conditions
- Influenza A Virus
- Interventions
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 102
- Registration Number
- NCT02532283
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Daratumumab Subcutaneous (SC) AdministrationDrug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT02519452
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 161
- Registration Number
- NCT02498392
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Phase 3
Completed
- Conditions
- Treatment-resistant Depression
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 802
- Registration Number
- NCT02497287
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
Phase 3
Completed
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 719
- Registration Number
- NCT02493868
Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)
Completed
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 330
- Registration Number
- NCT02489305
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT02477891
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02475161
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 193
- Registration Number
- NCT02473289
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Phase 2
Completed
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 326
- Registration Number
- NCT02472145
© Copyright 2025. All Rights Reserved by MedPath